[Effect of 3-(4-chlorphenyl-) 1-phenyl-1H-pyrazole-4-acetic acid (lonazolac-Ca), diclofenac-Na and indomethacin on the gastrointestinal blood loss].
According to a Latin Square-2 block study design gastrointestinal blood loss after medication with lonacolac-Ca (200 mg t.i.d.), diclofenac-Na (50 mg t.i.d.) and indomethacin (50 mg t.i.d.) was investigated in 6 healthy volunteers. Blood loss was estimated by measuring 51Cr-labelled erythrocytes in the faeces. Each active substance was taken for one week in randomized order, followed by a 7-day period of placebo administration (wash-out period). Stool samples were collected daily, also during placebo periods. Average weekly blood loss was 13.76 ml after lonacolac-Ca, 12.57 ml after diclofenac-Na and 23.687 ml after indomethacin. Blood loss was significantly lower with lonazolac-Ca and diclofenac-Na than with indomethacin (p less than 0.001). There is no difference statistically between the two former substances.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D004008:Diclofenac / Q000009:adverse effects*; D004064:Digestive System / Q000187:drug effects*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D010648:Phenylacetates / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D010648:Phenylacetates; D011720:Pyrazoles; C017472:lonazolac; D004008:Diclofenac; D007213:Indomethacin
Uber den Einfluss von 3-(4-Chlorphenyl-) 1-phenyl-1H-pyrazol-4-Essigsäure (Lonazolac-Ca), Diclofenac-Na und Indometacin auf die gastrointestinale Blutausscheidung.